Treatment with an FLT3i combined with an autophagy inhibitor, ROC-325 and Lys05 [64,65], showed a synergistic antileukemic effect in the FLT-ITD-positive mouse model and primary FLT3-ITD-positive AML cells [63]. Here, FLT3 is linked to acute myeloid leukemia.